Masaru Yamashita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masaru Yamashita has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Hiromi Nagano
Department of Otolaryngology Head and Neck Surgery Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan
10 shared publications - Hayato Matsumoto
Department of Otolaryngology Head and Neck Surgery Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan
7 shared publications - Takayuki Kyutoku
Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
7 shared publications - Satoshi Kiyama
Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
6 shared publications - Masatoyo Nakajo
Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Hiroyuki Iuchi
Kirishima Medical Center
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (12) , 5599-5605
Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma
Objectives: The purpose of this study is to investigate the genetic mutational status of recurrent/metastatic papillary thyroid carcinoma (PTC) and its prognostic implications. Methods: Data were analyzed for 348 consecutive patients with PTC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and February 2026. Genetic mutations were determined by next generation sequencing. Survival of patients was determined by log‐rank test and a Cox proportional hazards model. Results: The top 10 mutations in recurrent/metastatic PTC were TERT (82.2%), BRAF (78.7%), LTK (16.1%), CDKN2A (15.2%), KMT2D (14.4%), NOTCH3 (14.1%), TP53 (12.9%), PIK3CA (11.5%), CDKN2B (10.6%), STK11 (10.3%), with 11.0 ± 0.19 (mean ± SEM) mutations/individual. BRAF ( p = 0.0379), CDKN2A ( p = 7.41 × 10 −12 ), KMT2D ( p = 0.0048), PIK3CA ( p = 0.0406), CDKN2B ( p = 7.24 × 10 −13 ), and concurrent TERT/BRAF ( p = 0.0141) were associated with a significantly worse prognosis, as determined by log‐rank test. Multivariable Cox proportional hazards analysis was 3.762 (95% CI, 1.7480–8.095; p = 7.026 × 10 −4 ) for CDKN2A , 2.620 (1.50–4.575; p = 7.076 × 10 −4 ) for KMT2D, 1.882 (1.127–3.143; p = 0.01572) for concurrent TERT/BRAF . Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic PTC and identified several alterations with significant prognostic relevance. Even in advanced disease, specific mutations such as CDKN2A , KMT2D , and concurrent TERT/BRAF remained strongly associated with poor survival, underscoring the clinical value of comprehensive cancer genomic profiling in this population. Level of Evidence: 3.
- 17 August 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (12) , 5599-5605
Open AccessGenetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma
Objectives: The purpose of this study is to investigate the genetic mutational status of recurrent/metastatic papillary thyroid carcinoma (PTC) and its prognostic implications. Methods: Data were analyzed for 348 consecutive patients with PTC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and February 2026. Genetic mutations were determined by next generation sequencing. Survival of patients was determined by log‐rank test and a Cox proportional hazards model. Results: The top 10 mutations in recurrent/metastatic PTC were TERT (82.2%), BRAF (78.7%), LTK (16.1%), CDKN2A (15.2%), KMT2D (14.4%), NOTCH3 (14.1%), TP53 (12.9%), PIK3CA (11.5%), CDKN2B (10.6%), STK11 (10.3%), with 11.0 ± 0.19 (mean ± SEM) mutations/individual. BRAF ( p = 0.0379), CDKN2A ( p = 7.41 × 10 −12 ), KMT2D ( p = 0.0048), PIK3CA ( p = 0.0406), CDKN2B ( p = 7.24 × 10 −13 ), and concurrent TERT/BRAF ( p = 0.0141) were associated with a significantly worse prognosis, as determined by log‐rank test. Multivariable Cox proportional hazards analysis was 3.762 (95% CI, 1.7480–8.095; p = 7.026 × 10 −4 ) for CDKN2A , 2.620 (1.50–4.575; p = 7.076 × 10 −4 ) for KMT2D, 1.882 (1.127–3.143; p = 0.01572) for concurrent TERT/BRAF . Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic PTC and identified several alterations with significant prognostic relevance. Even in advanced disease, specific mutations such as CDKN2A , KMT2D , and concurrent TERT/BRAF remained strongly associated with poor survival, underscoring the clinical value of comprehensive cancer genomic profiling in this population. Level of Evidence: 3.
- 16 June 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (5) , 1-8
Genetic mutations in neuroendocrine carcinomas of unknown primary
Introduction: Although genetic mutations have been reported in neuroendocrine carcinomas of unknown primary (NECs-UP), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of NECs-UP and its potential therapeutic relevance.Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic NEC-UP.Materials and methods: Data were analyzed for 122 consecutive patients with NECs-UP registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and August 2025. Genetic mutations were determined by next-generation sequencing. Survival of patients was determined by log-rank test and a Cox proportional hazards model.Results: The top 10 mutations in NECs-UP were TP53 (71.3%), RB1 (49.2%), KMT2D (24.6%), NOTCH1 (20.5%), CDKN2A (18.0%), SPEN (15.6%), ARID1A (15.6%), RICTOR (15.6%), CIC (14.8%), SDHA (14.8%), with 16.3 7.1 (mean SD) mutations/individual. Mutation in TP53 (p = 0.0474) and CIC (p = 0.0322) were associated with a significantly worse prognosis, as determined by log-rank test. The hazard ratios for cases with this mutation was 2.0550 (95% CI, 1.0540-4.006, p = 0.03455) for CIC.Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic NECs-UP. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.
- 16 June 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (5) , 1-8
Genetic mutations in neuroendocrine carcinomas of unknown primary
Introduction: Although genetic mutations have been reported in neuroendocrine carcinomas of unknown primary (NECs-UP), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of NECs-UP and its potential therapeutic relevance.Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic NEC-UP.Materials and methods: Data were analyzed for 122 consecutive patients with NECs-UP registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and August 2025. Genetic mutations were determined by next-generation sequencing. Survival of patients was determined by log-rank test and a Cox proportional hazards model.Results: The top 10 mutations in NECs-UP were TP53 (71.3%), RB1 (49.2%), KMT2D (24.6%), NOTCH1 (20.5%), CDKN2A (18.0%), SPEN (15.6%), ARID1A (15.6%), RICTOR (15.6%), CIC (14.8%), SDHA (14.8%), with 16.3 7.1 (mean SD) mutations/individual. Mutation in TP53 (p = 0.0474) and CIC (p = 0.0322) were associated with a significantly worse prognosis, as determined by log-rank test. The hazard ratios for cases with this mutation was 2.0550 (95% CI, 1.0540-4.006, p = 0.03455) for CIC.Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic NECs-UP. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.
- 1 June 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (4) , 32-39
Genetic mutations in metastatic adenocarcinoma of unknown primary
Introduction: Although several genomic alterations have been reported in adenocarcinoma of unknown primary (ACUP), molecularly targeted therapies are not yet clinically established, and comprehensive genomic profiling (CGP) is rarely used in daily practice.Aim: To charaterize the molecular landscape and prognostic impact of key mutations in recurrent or metastatic ACUP.Materials and methods: Data from 480 consecutive ACUP patients registered in Japan’s National Cancer Center (C-CAT) between June 2019 and August 2025 were analyzed. Somatic mutations were identified using the FoundationOne CDx platform. Overall survival (OS) was assessed by Kaplan–Meier analysis, log-rank tests, and multivariate Cox proportional hazards modeling.Results: The most frequent alterations were TP53 (59.4%), KRAS (31.5%), CDKN2A (26.3%), KMT2D (22.3%), LTK (17.9%), NOTCH3 (16.9%), STK11 (16.3%), CDKN2B (15.8%), ERBB2 (15.4%), and GNAS (15.2%). Patients harbored a mean of 17.3 9.9 mutations per patient (mean SD). Mutations in GNAS (p = 0.046) and PIK3CA (p = 0.025) were associated with better OS, whereas ARID1A (p = 0.049) and NOTCH1 (p = 0.038) predicted worse OS. In Cox analysis, hazard ratios (HR [95% CI]) were 0.57 (0.36–0.92, p = 0.020) for GNAS, 0.57 (0.33–0.96, p = 0.033) for PIK3CA, 1.98 (1.27–3.09, p = 0.0024) for ARID1A, and 1.84 (1.17–2.91, p = 0.0090) for NOTCH1.Conclusions: GNAS and PIK3CA mutations were linked to favorable outcomes, while ARID1A and NOTCH1 alterations indicated poor prognosis in ACUP. These results highlight the prognostic significance of specific genomic alterations and support integrating CGP into the clinical management of ACUP.
- 1 June 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (4) , 32-39
Genetic mutations in metastatic adenocarcinoma of unknown primary
Introduction: Although several genomic alterations have been reported in adenocarcinoma of unknown primary (ACUP), molecularly targeted therapies are not yet clinically established, and comprehensive genomic profiling (CGP) is rarely used in daily practice.Aim: To charaterize the molecular landscape and prognostic impact of key mutations in recurrent or metastatic ACUP.Materials and methods: Data from 480 consecutive ACUP patients registered in Japan’s National Cancer Center (C-CAT) between June 2019 and August 2025 were analyzed. Somatic mutations were identified using the FoundationOne CDx platform. Overall survival (OS) was assessed by Kaplan–Meier analysis, log-rank tests, and multivariate Cox proportional hazards modeling.Results: The most frequent alterations were TP53 (59.4%), KRAS (31.5%), CDKN2A (26.3%), KMT2D (22.3%), LTK (17.9%), NOTCH3 (16.9%), STK11 (16.3%), CDKN2B (15.8%), ERBB2 (15.4%), and GNAS (15.2%). Patients harbored a mean of 17.3 9.9 mutations per patient (mean SD). Mutations in GNAS (p = 0.046) and PIK3CA (p = 0.025) were associated with better OS, whereas ARID1A (p = 0.049) and NOTCH1 (p = 0.038) predicted worse OS. In Cox analysis, hazard ratios (HR [95% CI]) were 0.57 (0.36–0.92, p = 0.020) for GNAS, 0.57 (0.33–0.96, p = 0.033) for PIK3CA, 1.98 (1.27–3.09, p = 0.0024) for ARID1A, and 1.84 (1.17–2.91, p = 0.0090) for NOTCH1.Conclusions: GNAS and PIK3CA mutations were linked to favorable outcomes, while ARID1A and NOTCH1 alterations indicated poor prognosis in ACUP. These results highlight the prognostic significance of specific genomic alterations and support integrating CGP into the clinical management of ACUP.
- 19 March 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (3) , 7-13
Genetic mutations in salivary duct carcinoma
Introduction: Although genetic mutations have been reported in salivary duct carcinoma (SDC), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of SDC and its potential therapeutic relevance. Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic SDC. Materials and methods: Data were analyzed for 207 consecutive patients with SDC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and October 2025. Genetic mutations were determined by next-generation sequencing. Survival of patients was determined by the log-rank test and the Cox proportional hazards model. Results: The top 10 mutations in SDC were TP53 (74.4%), ERBB2 (52.2%), NF1 (32.4%), CDK12 (29.0%), PIK3CA (28.0%), NOTCH3 (19.8%), LTK (18.4%), CDKN2A (18.4%), BRCA2 (16.9%), SPEN (16.9%), with 17.1 7.2 (mean standard error of the mean [SEM]) mutations/individual. TP53 mutations (p = 0.005707) were associated with a significantly worse prognosis, as determined by log-rank test. The hazard ratios for cases with this mutation was 2.6390 (95% CI, 1.2180–5.720, p = 0.0139) for TP53. Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic SDC. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.
- 19 March 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (3) , 7-13
Genetic mutations in salivary duct carcinoma
Introduction: Although genetic mutations have been reported in salivary duct carcinoma (SDC), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of SDC and its potential therapeutic relevance. Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic SDC. Materials and methods: Data were analyzed for 207 consecutive patients with SDC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and October 2025. Genetic mutations were determined by next-generation sequencing. Survival of patients was determined by the log-rank test and the Cox proportional hazards model. Results: The top 10 mutations in SDC were TP53 (74.4%), ERBB2 (52.2%), NF1 (32.4%), CDK12 (29.0%), PIK3CA (28.0%), NOTCH3 (19.8%), LTK (18.4%), CDKN2A (18.4%), BRCA2 (16.9%), SPEN (16.9%), with 17.1 7.2 (mean standard error of the mean [SEM]) mutations/individual. TP53 mutations (p = 0.005707) were associated with a significantly worse prognosis, as determined by log-rank test. The hazard ratios for cases with this mutation was 2.6390 (95% CI, 1.2180–5.720, p = 0.0139) for TP53. Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic SDC. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.
- 23 February 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (2) , 31-38
Genetic mutations in recurrent and/or metastatic nasal carcinoma: A pathological comparison based on the Japanese national genomic profiling database
Introduction: Comprehensive genome profiling (CGP) has been reimbursed under Japan’s national health insurance since 2019 for patients with advanced solid tumors, including head and neck cancers. Despite this, genomic insights into rare nasal carcinoma subtypes remain limited, hindering subtype-specific therapeutic strategies. Aim: To characterize the genetic mutational profiles of recurrent and/or metastatic nasal carcinoma across histological subtypes using data from the Japanese National Genomic Profiling Database. Materials and methods: Genomic data from 135 patients with nasal carcinoma were analyzed, including squamous cell carcinoma (SCC) (n = 48), neuroendocrine tumor (NET) (n = 52), adenocarcinoma (n = 20), and undifferentiated carcinoma (n = 15). All cases were registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center Japan, between June 2019 and May 2025. Mutations were identified via FoundationOne CDx next-generation sequencing. Survival analysis employed the log-rank test and Cox proportional hazards model. Results: TP53 and KMT2D were frequently mutated across all subtypes. In SCC, KMT2D (p = 0.03), EGFR (p = 6.4 × 10-), and RICTOR (p = 0.03) mutations correlated with poor prognosis. No significant differences were found among subtypes in mutation count or tumor mutational burden (TMB). Discussion: Shared and distinct mutational patterns were observed, with prognostic relevance in SCC. These findings underscore the importance of genomic stratification in rare nasal carcinomas. Conclusions: CGP reveals key genetic drivers in nasal carcinoma, supporting its role in precision oncology and informing future subtype-specific therapeutic approaches.
- 23 February 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (2) , 31-38
Genetic mutations in recurrent and/or metastatic nasal carcinoma: A pathological comparison based on the Japanese national genomic profiling database
Introduction: Comprehensive genome profiling (CGP) has been reimbursed under Japan’s national health insurance since 2019 for patients with advanced solid tumors, including head and neck cancers. Despite this, genomic insights into rare nasal carcinoma subtypes remain limited, hindering subtype-specific therapeutic strategies. Aim: To characterize the genetic mutational profiles of recurrent and/or metastatic nasal carcinoma across histological subtypes using data from the Japanese National Genomic Profiling Database. Materials and methods: Genomic data from 135 patients with nasal carcinoma were analyzed, including squamous cell carcinoma (SCC) (n = 48), neuroendocrine tumor (NET) (n = 52), adenocarcinoma (n = 20), and undifferentiated carcinoma (n = 15). All cases were registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center Japan, between June 2019 and May 2025. Mutations were identified via FoundationOne CDx next-generation sequencing. Survival analysis employed the log-rank test and Cox proportional hazards model. Results: TP53 and KMT2D were frequently mutated across all subtypes. In SCC, KMT2D (p = 0.03), EGFR (p = 6.4 × 10-), and RICTOR (p = 0.03) mutations correlated with poor prognosis. No significant differences were found among subtypes in mutation count or tumor mutational burden (TMB). Discussion: Shared and distinct mutational patterns were observed, with prognostic relevance in SCC. These findings underscore the importance of genomic stratification in rare nasal carcinomas. Conclusions: CGP reveals key genetic drivers in nasal carcinoma, supporting its role in precision oncology and informing future subtype-specific therapeutic approaches.
- 20 February 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (1) , 24-31
Epicutaneous sensitization in BALB/c mice induces stronger systemic Th2 inflammation than intranasal sensitization despite comparable nasal eosinophilia
Introduction: Epicutaneous sensitization (ES) plays a role in the onset of allergic diseases such as atopic dermatitis (AD), bronchial asthma, and food allergies, but its effects on nasal allergic diseases remain unclear. Aim: The aim of this study was to compare the effects of intranasal challenge following ES with those following intranasal sensitization (NS) on nasal allergic inflammation. Materials and methods: Female BALB/c mice were sensitized epicutaneously or intranasally with 25 μg of ovalbumin (OVA) and 2 μg of cholera toxin (CT) six times at weekly intervals. These groups were compared with control groups that received ES with phosphate- buffered saline (PBS) alone, OVA alone, or CT alone. Two weeks after the final sensitization, the mice were challenged intranasally with 500 μg of OVA ten times over a two-week period. Four weeks after the final sensitization, allergic inflammation in the nasal cavity, OVA-specific IgE production, and cytokine profiles were evaluated in the different groups. Results: Post-challenge, there was no significant difference in the number of eosinophils or the thickness of lateral nasal mucosa between the ES and NS groups. However, the serum level of OVA-specific IgE in the ES group was significantly higher than that in the control and NS groups. Levels of IL-4, IL-5, IL-13, and IL-33 in CD4+ T cells were also significantly higher in the ES group than in the NS group. Conclusions: These results indicate that intranasal challenge following ES induces comparable eosinophilic inflammation in the nasal cavity, but elicits a stronger systemic Th2-type inflammatory response than that following NS.
- 20 February 2026
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 80 (1) , 24-31
Epicutaneous sensitization in BALB/c mice induces stronger systemic Th2 inflammation than intranasal sensitization despite comparable nasal eosinophilia
Introduction: Epicutaneous sensitization (ES) plays a role in the onset of allergic diseases such as atopic dermatitis (AD), bronchial asthma, and food allergies, but its effects on nasal allergic diseases remain unclear. Aim: The aim of this study was to compare the effects of intranasal challenge following ES with those following intranasal sensitization (NS) on nasal allergic inflammation. Materials and methods: Female BALB/c mice were sensitized epicutaneously or intranasally with 25 μg of ovalbumin (OVA) and 2 μg of cholera toxin (CT) six times at weekly intervals. These groups were compared with control groups that received ES with phosphate- buffered saline (PBS) alone, OVA alone, or CT alone. Two weeks after the final sensitization, the mice were challenged intranasally with 500 μg of OVA ten times over a two-week period. Four weeks after the final sensitization, allergic inflammation in the nasal cavity, OVA-specific IgE production, and cytokine profiles were evaluated in the different groups. Results: Post-challenge, there was no significant difference in the number of eosinophils or the thickness of lateral nasal mucosa between the ES and NS groups. However, the serum level of OVA-specific IgE in the ES group was significantly higher than that in the control and NS groups. Levels of IL-4, IL-5, IL-13, and IL-33 in CD4+ T cells were also significantly higher in the ES group than in the NS group. Conclusions: These results indicate that intranasal challenge following ES induces comparable eosinophilic inflammation in the nasal cavity, but elicits a stronger systemic Th2-type inflammatory response than that following NS.
- Open Access
Low-Extrusion-Force Injectable Chitosan Gel Microparticles for Effective Wound Dressing in Endoscopic Sinus Surgery
Chitosan hydrogels are effective wound dressings that promote healing through the synergy of chitosan’s inherent biological properties and the moist environment they maintain. We previously developed hydrogel microparticles using a highly biocompatible chitosan derivative with superior therapeutic effects. This study aimed to enhance their clinical translation for Endoscopic Sinus Surgery (ESS) by optimizing preparation conditions to achieve an extrusion force of w/v), we successfully reduced the maximum extrusion force to below 20 N (17 ± 1 N). These results demonstrate that the optimized injectable chitosan gel microparticles achieve the practical usability required for precise surgical maneuvers during ESS.
Open AccessLow-Extrusion-Force Injectable Chitosan Gel Microparticles for Effective Wound Dressing in Endoscopic Sinus Surgery
Chitosan hydrogels are effective wound dressings that promote healing through the synergy of chitosan’s inherent biological properties and the moist environment they maintain. We previously developed hydrogel microparticles using a highly biocompatible chitosan derivative with superior therapeutic effects. This study aimed to enhance their clinical translation for Endoscopic Sinus Surgery (ESS) by optimizing preparation conditions to achieve an extrusion force of w/v), we successfully reduced the maximum extrusion force to below 20 N (17 ± 1 N). These results demonstrate that the optimized injectable chitosan gel microparticles achieve the practical usability required for precise surgical maneuvers during ESS.
- 26 November 2025
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 79 (6) , 29-34
Genetic mutations in recurrent and/or metastatic squamous cell carcinoma of unknown primary – an analysis of the Japanese national genomic profiling database
Introduction: Although genetic mutations have been reported in squamous cell carcinoma of unknown primary (SCCUP), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of SCCUP and its potential therapeutic relevance.Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic SCCUP.Materials and methods: Data were analyzed for 170 consecutive patients with SCCUP registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and August 2025. Genetic mutations were determined by next-generation sequencing. The survival of patients was determined by the log-rank test and a Cox proportional hazards model.Results: The top 10 mutations in SCCUP were TP53 (57.6%), CDKN2A (37.0%), PIK3CA (32.9%), KMT2D (27.6%), CDKN2B (20.6%), NOTCH3 (20.6%), BRAC2 (20.0%), PTEN (16.5%), NOTCH1 (15.9%), and RICTOR (15.9%), with 20.2 10.1 (mean SEM) mutations/ individual. Mutation in BRCA2 (p = 0.0347) was associated with a significantly worse prognosis, as determined by the log-rank test. The hazard ratios for cases with this mutation was 2.3450 (95% CI, 1.2220–4.499, p = 0.01037) for BRCA2.Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic SCCUP. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.
- 26 November 2025
- Published by Index Copernicus in Otolaryngologia Polska
- Vol. 79 (6) , 29-34
Genetic mutations in recurrent and/or metastatic squamous cell carcinoma of unknown primary – an analysis of the Japanese national genomic profiling database
Introduction: Although genetic mutations have been reported in squamous cell carcinoma of unknown primary (SCCUP), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of SCCUP and its potential therapeutic relevance.Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic SCCUP.Materials and methods: Data were analyzed for 170 consecutive patients with SCCUP registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and August 2025. Genetic mutations were determined by next-generation sequencing. The survival of patients was determined by the log-rank test and a Cox proportional hazards model.Results: The top 10 mutations in SCCUP were TP53 (57.6%), CDKN2A (37.0%), PIK3CA (32.9%), KMT2D (27.6%), CDKN2B (20.6%), NOTCH3 (20.6%), BRAC2 (20.0%), PTEN (16.5%), NOTCH1 (15.9%), and RICTOR (15.9%), with 20.2 10.1 (mean SEM) mutations/ individual. Mutation in BRCA2 (p = 0.0347) was associated with a significantly worse prognosis, as determined by the log-rank test. The hazard ratios for cases with this mutation was 2.3450 (95% CI, 1.2220–4.499, p = 0.01037) for BRCA2.Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic SCCUP. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.
- Open Access
- 7 March 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (2) , e70110
Mutations in Anaplastic Thyroid Carcinoma: An Analysis of the Japanese National Genomic Database
Objectives: The purpose of this study is to investigate the genetic mutational status of anaplastic thyroid carcinoma (ATC) and its prognostic implications.Methods: Data were analyzed for 129 consecutive patients with ATC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and June 2024. Genetic alterations were determined by FoundationOne CDx or Liquid CDx next‐generation sequencing. The survival of patients was determined by the log‐rank test and a Cox proportional hazards model.Results: The top 30 mutations in ATC were TERT (98/129), TP53 (88/129), BRAF (72/129), CDKN2A (39/129), CDKN2B (29/129), LTK (26/129), NRAS (25/129), KMT2D (24/129), PIK3CA (26/129), NOTCH3 (27/129), NF2 (19/129), MTAP (17/129), TET2 (16/129), STK11 (15/129), ATM (14/129), FANCA (14/129), NF1 (13/129), DNMT3A (13/129), KIT (13/129), NOTCH1 (13/129), EP300 (12/129), BRCA2 (11/129), CARD11 (11/129), KEL (11/129), MSH3 (11/129), PTEN (11/129), RICTOR (11/129), TSC1 (11/129), ROS1 (10/129), and KMT2A (10/129) with 13.7 ± 0.5 (mean ± SEM) mutations/individual. Mutations in BRAF (p = 0.003), PIK3CA (p = 0.014), and BRCA2 (p = 0.036) were associated with a significantly better prognosis, whereas mutations in STK11 (p = 0.024) was associated with a significantly worse prognosis, as determined by log‐rank tests. The hazard ratios for cases with these mutations were 0.248 (95% CI, 0.0973–0.633, p = 3.5 × 10−3) for PIK3CA, 2.410 (1.054–5.515, p = 0.037) for STK11, and 0.157 (0.0376–0.659, p = 0.011) for BRCA2.Conclusions: In ATC, PIK3CA, and BRCA2 mutations were associated with a better prognosis, and STK11 mutation was associated with a poorer prognosis in this study.Level of Evidence: 3.
- 7 March 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (2) , e70110
Open AccessMutations in Anaplastic Thyroid Carcinoma: An Analysis of the Japanese National Genomic Database
Objectives: The purpose of this study is to investigate the genetic mutational status of anaplastic thyroid carcinoma (ATC) and its prognostic implications.Methods: Data were analyzed for 129 consecutive patients with ATC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and June 2024. Genetic alterations were determined by FoundationOne CDx or Liquid CDx next‐generation sequencing. The survival of patients was determined by the log‐rank test and a Cox proportional hazards model.Results: The top 30 mutations in ATC were TERT (98/129), TP53 (88/129), BRAF (72/129), CDKN2A (39/129), CDKN2B (29/129), LTK (26/129), NRAS (25/129), KMT2D (24/129), PIK3CA (26/129), NOTCH3 (27/129), NF2 (19/129), MTAP (17/129), TET2 (16/129), STK11 (15/129), ATM (14/129), FANCA (14/129), NF1 (13/129), DNMT3A (13/129), KIT (13/129), NOTCH1 (13/129), EP300 (12/129), BRCA2 (11/129), CARD11 (11/129), KEL (11/129), MSH3 (11/129), PTEN (11/129), RICTOR (11/129), TSC1 (11/129), ROS1 (10/129), and KMT2A (10/129) with 13.7 ± 0.5 (mean ± SEM) mutations/individual. Mutations in BRAF (p = 0.003), PIK3CA (p = 0.014), and BRCA2 (p = 0.036) were associated with a significantly better prognosis, whereas mutations in STK11 (p = 0.024) was associated with a significantly worse prognosis, as determined by log‐rank tests. The hazard ratios for cases with these mutations were 0.248 (95% CI, 0.0973–0.633, p = 3.5 × 10−3) for PIK3CA, 2.410 (1.054–5.515, p = 0.037) for STK11, and 0.157 (0.0376–0.659, p = 0.011) for BRCA2.Conclusions: In ATC, PIK3CA, and BRCA2 mutations were associated with a better prognosis, and STK11 mutation was associated with a poorer prognosis in this study.Level of Evidence: 3.
- 23 September 2024
- Published by SAGE Publications in Tissue Engineering Part B: Reviews
Trends in Injectable Biomaterials for Vocal Fold Regeneration and Long-Term Augmentation
Human vocal folds (VF), a pair of small, soft tissues in the larynx, have a layered mucosal structure with unique mechanical strength to support high-level tissue deformation by phonation. Severe pathological changes to VF have causes including surgery, trauma, age-related atrophy, and radiation, and lead to partial or complete communication loss and difficulty in breathing and swallowing. VF glottal insufficiency requires injectable VF biomaterials such as hyaluronan, calcium hydroxyapatite, and autologous fat to augment VF functions. Although these biomaterials provide an effective short-term solution, significant variations in patient response and requirements of repeat reinjection remain notable challenges in clinical practice. Tissue engineering strategies have been actively explored in the search of an injectable biomaterial that possesses the capacity to match native tissue's material properties while promoting permanent tissue regeneration. This review aims to assess the current status of biomaterial development in VF tissue engineering. The focus will be on examining state-of-the-art techniques including modification with bioactive molecules, cell encapsulation, composite materials, as well as, in situ crosslinking with click chemistry. We will discuss potential opportunities that can further leverage these engineering techniques in the advancement of VF injectable biomaterials.
- 23 September 2024
- Published by SAGE Publications in Tissue Engineering Part B: Reviews
Trends in Injectable Biomaterials for Vocal Fold Regeneration and Long-Term Augmentation
Human vocal folds (VF), a pair of small, soft tissues in the larynx, have a layered mucosal structure with unique mechanical strength to support high-level tissue deformation by phonation. Severe pathological changes to VF have causes including surgery, trauma, age-related atrophy, and radiation, and lead to partial or complete communication loss and difficulty in breathing and swallowing. VF glottal insufficiency requires injectable VF biomaterials such as hyaluronan, calcium hydroxyapatite, and autologous fat to augment VF functions. Although these biomaterials provide an effective short-term solution, significant variations in patient response and requirements of repeat reinjection remain notable challenges in clinical practice. Tissue engineering strategies have been actively explored in the search of an injectable biomaterial that possesses the capacity to match native tissue's material properties while promoting permanent tissue regeneration. This review aims to assess the current status of biomaterial development in VF tissue engineering. The focus will be on examining state-of-the-art techniques including modification with bioactive molecules, cell encapsulation, composite materials, as well as, in situ crosslinking with click chemistry. We will discuss potential opportunities that can further leverage these engineering techniques in the advancement of VF injectable biomaterials.